ANKE BIO(SZ:300009)2022-12-08 09:22Group 1: Company Overview - The company follows a "one main, two wings" development strategy, focusing on core business and complementary external growth [1][3] - Recent acquisitions include Beijing Huimin Traditional Chinese Medicine Children's Hospital and a planned acquisition of Anhui Zeping Pharmaceutical [3][4] - The principles for external growth include complementarity with existing business, certain R&D capabilities, and being a well-developed entity [3][4] Group 2: Management and Sales Strategy - Key executives have specific roles: marketing, R&D, and sales channel improvements for traditional Chinese medicine [2][4] - The sales strategy for traditional Chinese medicine involves both commercial partnerships and direct sales to hospitals [4][5] - Performance evaluation for subsidiaries is linked to equity incentives, focusing on management teams [2][4] Group 3: Product Development and Market Strategy - Future product development aims to enhance competitiveness, with growth factors including clinical trials for long-acting interferon and growth hormone [4][5] - The marketing team has focused on pediatric growth issues, utilizing a three-year strategy to capture market share [4][5] - The company is expanding into the health sector, indicating a strategic direction towards health-related products [4][5] Group 4: Sales Projections and Market Opportunities - Sales of interferon and growth hormone are expected to maintain current growth rates, supported by marketing efforts and favorable national policies [5] - Increased investment in new product development is anticipated to diversify the product line and enhance marketing effectiveness [5]